Experimental and Therapeutic Medicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2098379, encodeId=dabe20983e9ce, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：9-24从oncology letter transfer过来，10-11小修，10-24返修，11-02润色后提交，11-03accept，一篇临床case，总体来说处理速度不慢，运气还不错，等待后续proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/02/c1a3d2d90ee1a88e8ee6415e4607e819.jpg, createdBy=e2622415808, createdName=Allen灬Walker, createdTime=Thu Nov 03 23:35:26 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145960, encodeId=7fd12145960c0, content=有人知道这个期刊最新情况嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/RHTJcPEoCibkIraBo1cDLcpFWGqcHzibDxMEgIvzKhO9uSnaZtFFLXcS9BhCsyX87KpoHViarOCD1Vn8dYL7RC3ng/0, createdBy=849a2163679, createdName=程南枫, createdTime=Sun Jul 02 15:13:46 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126420, encodeId=019f2126420f0, content=偏重的研究方向：基础 经验分享：Word版proof，引文怎么插入啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbc25508529, createdName=Ddffffg, createdTime=Mon Apr 17 06:41:27 CST 2023, time=2023-04-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127258, encodeId=988f212e2586d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：缺点是慢。审稿还是认真。尤其是编辑，审稿人没有什么意见，最后editor 提的问题对文章提升很用用。还有就是接收以后还不断提问。。。。没有说的那么烂吧，编辑还是在努力帮助提高文章质量, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=722f2896174, createdName=pinger3557219, createdTime=Thu Apr 20 14:47:41 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=585480, encodeId=b276585480af, content=惊现审稿人Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿Dr. H 2020-02-14 00:00:00 发表: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, beContent=Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/0380108019204f323435b170194e7f28.jpg, createdBy=b43b5142498, createdName=1467c2d1m03暂无昵称, createdTime=Thu Feb 27 00:00:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120372, encodeId=99f921203e2d7, content=Proof ready 到invoice要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d74b8191744, createdName=ms2000000382061930, createdTime=Sun Mar 19 02:03:00 CST 2023, time=2023-03-19, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119810, encodeId=2b952119810ec, content=想问问一审大修之后还会修回给外审专家麽，还是编辑直接决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=008c8298477, createdName=ms1000001124557483, createdTime=Wed Mar 15 22:29:44 CST 2023, time=2023-03-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=914685, encodeId=5d0991468532, content=请问1月3号提交的手稿，现在还是submitted状态，是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72f5442032, createdName=ms9000000803041131, createdTime=Fri Jan 08 17:25:36 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后，在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省)]

2022-11-03 Allen灬Walker

审稿速度:2.0 | 投稿命中率:75.0
经验分享：9-24从oncology letter transfer过来，10-11小修，10-24返修，11-02润色后提交，11-03accept，一篇临床case，总体来说处理速度不慢，运气还不错，等待后续proof

42 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2098379, encodeId=dabe20983e9ce, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：9-24从oncology letter transfer过来，10-11小修，10-24返修，11-02润色后提交，11-03accept，一篇临床case，总体来说处理速度不慢，运气还不错，等待后续proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/02/c1a3d2d90ee1a88e8ee6415e4607e819.jpg, createdBy=e2622415808, createdName=Allen灬Walker, createdTime=Thu Nov 03 23:35:26 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145960, encodeId=7fd12145960c0, content=有人知道这个期刊最新情况嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/RHTJcPEoCibkIraBo1cDLcpFWGqcHzibDxMEgIvzKhO9uSnaZtFFLXcS9BhCsyX87KpoHViarOCD1Vn8dYL7RC3ng/0, createdBy=849a2163679, createdName=程南枫, createdTime=Sun Jul 02 15:13:46 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126420, encodeId=019f2126420f0, content=偏重的研究方向：基础 经验分享：Word版proof，引文怎么插入啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbc25508529, createdName=Ddffffg, createdTime=Mon Apr 17 06:41:27 CST 2023, time=2023-04-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127258, encodeId=988f212e2586d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：缺点是慢。审稿还是认真。尤其是编辑，审稿人没有什么意见，最后editor 提的问题对文章提升很用用。还有就是接收以后还不断提问。。。。没有说的那么烂吧，编辑还是在努力帮助提高文章质量, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=722f2896174, createdName=pinger3557219, createdTime=Thu Apr 20 14:47:41 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=585480, encodeId=b276585480af, content=惊现审稿人Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿Dr. H 2020-02-14 00:00:00 发表: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, beContent=Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/0380108019204f323435b170194e7f28.jpg, createdBy=b43b5142498, createdName=1467c2d1m03暂无昵称, createdTime=Thu Feb 27 00:00:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120372, encodeId=99f921203e2d7, content=Proof ready 到invoice要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d74b8191744, createdName=ms2000000382061930, createdTime=Sun Mar 19 02:03:00 CST 2023, time=2023-03-19, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119810, encodeId=2b952119810ec, content=想问问一审大修之后还会修回给外审专家麽，还是编辑直接决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=008c8298477, createdName=ms1000001124557483, createdTime=Wed Mar 15 22:29:44 CST 2023, time=2023-03-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=914685, encodeId=5d0991468532, content=请问1月3号提交的手稿，现在还是submitted状态，是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72f5442032, createdName=ms9000000803041131, createdTime=Fri Jan 08 17:25:36 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后，在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省)]

2023-07-02 程南枫

有人知道这个期刊最新情况嘛？

27 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2098379, encodeId=dabe20983e9ce, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：9-24从oncology letter transfer过来，10-11小修，10-24返修，11-02润色后提交，11-03accept，一篇临床case，总体来说处理速度不慢，运气还不错，等待后续proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/02/c1a3d2d90ee1a88e8ee6415e4607e819.jpg, createdBy=e2622415808, createdName=Allen灬Walker, createdTime=Thu Nov 03 23:35:26 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145960, encodeId=7fd12145960c0, content=有人知道这个期刊最新情况嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/RHTJcPEoCibkIraBo1cDLcpFWGqcHzibDxMEgIvzKhO9uSnaZtFFLXcS9BhCsyX87KpoHViarOCD1Vn8dYL7RC3ng/0, createdBy=849a2163679, createdName=程南枫, createdTime=Sun Jul 02 15:13:46 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126420, encodeId=019f2126420f0, content=偏重的研究方向：基础 经验分享：Word版proof，引文怎么插入啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbc25508529, createdName=Ddffffg, createdTime=Mon Apr 17 06:41:27 CST 2023, time=2023-04-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127258, encodeId=988f212e2586d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：缺点是慢。审稿还是认真。尤其是编辑，审稿人没有什么意见，最后editor 提的问题对文章提升很用用。还有就是接收以后还不断提问。。。。没有说的那么烂吧，编辑还是在努力帮助提高文章质量, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=722f2896174, createdName=pinger3557219, createdTime=Thu Apr 20 14:47:41 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=585480, encodeId=b276585480af, content=惊现审稿人Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿Dr. H 2020-02-14 00:00:00 发表: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, beContent=Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/0380108019204f323435b170194e7f28.jpg, createdBy=b43b5142498, createdName=1467c2d1m03暂无昵称, createdTime=Thu Feb 27 00:00:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120372, encodeId=99f921203e2d7, content=Proof ready 到invoice要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d74b8191744, createdName=ms2000000382061930, createdTime=Sun Mar 19 02:03:00 CST 2023, time=2023-03-19, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119810, encodeId=2b952119810ec, content=想问问一审大修之后还会修回给外审专家麽，还是编辑直接决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=008c8298477, createdName=ms1000001124557483, createdTime=Wed Mar 15 22:29:44 CST 2023, time=2023-03-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=914685, encodeId=5d0991468532, content=请问1月3号提交的手稿，现在还是submitted状态，是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72f5442032, createdName=ms9000000803041131, createdTime=Fri Jan 08 17:25:36 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后，在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省)]

2023-04-17 Ddffffg 来自上海

偏重的研究方向：基础
经验分享：Word版proof，引文怎么插入啊

27 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2098379, encodeId=dabe20983e9ce, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：9-24从oncology letter transfer过来，10-11小修，10-24返修，11-02润色后提交，11-03accept，一篇临床case，总体来说处理速度不慢，运气还不错，等待后续proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/02/c1a3d2d90ee1a88e8ee6415e4607e819.jpg, createdBy=e2622415808, createdName=Allen灬Walker, createdTime=Thu Nov 03 23:35:26 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145960, encodeId=7fd12145960c0, content=有人知道这个期刊最新情况嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/RHTJcPEoCibkIraBo1cDLcpFWGqcHzibDxMEgIvzKhO9uSnaZtFFLXcS9BhCsyX87KpoHViarOCD1Vn8dYL7RC3ng/0, createdBy=849a2163679, createdName=程南枫, createdTime=Sun Jul 02 15:13:46 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126420, encodeId=019f2126420f0, content=偏重的研究方向：基础 经验分享：Word版proof，引文怎么插入啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbc25508529, createdName=Ddffffg, createdTime=Mon Apr 17 06:41:27 CST 2023, time=2023-04-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127258, encodeId=988f212e2586d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：缺点是慢。审稿还是认真。尤其是编辑，审稿人没有什么意见，最后editor 提的问题对文章提升很用用。还有就是接收以后还不断提问。。。。没有说的那么烂吧，编辑还是在努力帮助提高文章质量, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=722f2896174, createdName=pinger3557219, createdTime=Thu Apr 20 14:47:41 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=585480, encodeId=b276585480af, content=惊现审稿人Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿Dr. H 2020-02-14 00:00:00 发表: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, beContent=Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/0380108019204f323435b170194e7f28.jpg, createdBy=b43b5142498, createdName=1467c2d1m03暂无昵称, createdTime=Thu Feb 27 00:00:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120372, encodeId=99f921203e2d7, content=Proof ready 到invoice要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d74b8191744, createdName=ms2000000382061930, createdTime=Sun Mar 19 02:03:00 CST 2023, time=2023-03-19, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119810, encodeId=2b952119810ec, content=想问问一审大修之后还会修回给外审专家麽，还是编辑直接决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=008c8298477, createdName=ms1000001124557483, createdTime=Wed Mar 15 22:29:44 CST 2023, time=2023-03-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=914685, encodeId=5d0991468532, content=请问1月3号提交的手稿，现在还是submitted状态，是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72f5442032, createdName=ms9000000803041131, createdTime=Fri Jan 08 17:25:36 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后，在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省)]

2022-02-01 ms2000000130062631

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：基础研究;糖尿病
经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投

69 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2098379, encodeId=dabe20983e9ce, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：9-24从oncology letter transfer过来，10-11小修，10-24返修，11-02润色后提交，11-03accept，一篇临床case，总体来说处理速度不慢，运气还不错，等待后续proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/02/c1a3d2d90ee1a88e8ee6415e4607e819.jpg, createdBy=e2622415808, createdName=Allen灬Walker, createdTime=Thu Nov 03 23:35:26 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145960, encodeId=7fd12145960c0, content=有人知道这个期刊最新情况嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/RHTJcPEoCibkIraBo1cDLcpFWGqcHzibDxMEgIvzKhO9uSnaZtFFLXcS9BhCsyX87KpoHViarOCD1Vn8dYL7RC3ng/0, createdBy=849a2163679, createdName=程南枫, createdTime=Sun Jul 02 15:13:46 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126420, encodeId=019f2126420f0, content=偏重的研究方向：基础 经验分享：Word版proof，引文怎么插入啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbc25508529, createdName=Ddffffg, createdTime=Mon Apr 17 06:41:27 CST 2023, time=2023-04-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127258, encodeId=988f212e2586d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：缺点是慢。审稿还是认真。尤其是编辑，审稿人没有什么意见，最后editor 提的问题对文章提升很用用。还有就是接收以后还不断提问。。。。没有说的那么烂吧，编辑还是在努力帮助提高文章质量, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=722f2896174, createdName=pinger3557219, createdTime=Thu Apr 20 14:47:41 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=585480, encodeId=b276585480af, content=惊现审稿人Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿Dr. H 2020-02-14 00:00:00 发表: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, beContent=Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/0380108019204f323435b170194e7f28.jpg, createdBy=b43b5142498, createdName=1467c2d1m03暂无昵称, createdTime=Thu Feb 27 00:00:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120372, encodeId=99f921203e2d7, content=Proof ready 到invoice要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d74b8191744, createdName=ms2000000382061930, createdTime=Sun Mar 19 02:03:00 CST 2023, time=2023-03-19, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119810, encodeId=2b952119810ec, content=想问问一审大修之后还会修回给外审专家麽，还是编辑直接决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=008c8298477, createdName=ms1000001124557483, createdTime=Wed Mar 15 22:29:44 CST 2023, time=2023-03-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=914685, encodeId=5d0991468532, content=请问1月3号提交的手稿，现在还是submitted状态，是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72f5442032, createdName=ms9000000803041131, createdTime=Fri Jan 08 17:25:36 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后，在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省)]

2023-04-20 pinger3557219 来自广东省

审稿速度:3.0 | 投稿命中率:75.0
经验分享：缺点是慢。审稿还是认真。尤其是编辑，审稿人没有什么意见，最后editor 提的问题对文章提升很用用。还有就是接收以后还不断提问。。。。没有说的那么烂吧，编辑还是在努力帮助提高文章质量

34 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2098379, encodeId=dabe20983e9ce, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：9-24从oncology letter transfer过来，10-11小修，10-24返修，11-02润色后提交，11-03accept，一篇临床case，总体来说处理速度不慢，运气还不错，等待后续proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/02/c1a3d2d90ee1a88e8ee6415e4607e819.jpg, createdBy=e2622415808, createdName=Allen灬Walker, createdTime=Thu Nov 03 23:35:26 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145960, encodeId=7fd12145960c0, content=有人知道这个期刊最新情况嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/RHTJcPEoCibkIraBo1cDLcpFWGqcHzibDxMEgIvzKhO9uSnaZtFFLXcS9BhCsyX87KpoHViarOCD1Vn8dYL7RC3ng/0, createdBy=849a2163679, createdName=程南枫, createdTime=Sun Jul 02 15:13:46 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126420, encodeId=019f2126420f0, content=偏重的研究方向：基础 经验分享：Word版proof，引文怎么插入啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbc25508529, createdName=Ddffffg, createdTime=Mon Apr 17 06:41:27 CST 2023, time=2023-04-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127258, encodeId=988f212e2586d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：缺点是慢。审稿还是认真。尤其是编辑，审稿人没有什么意见，最后editor 提的问题对文章提升很用用。还有就是接收以后还不断提问。。。。没有说的那么烂吧，编辑还是在努力帮助提高文章质量, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=722f2896174, createdName=pinger3557219, createdTime=Thu Apr 20 14:47:41 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=585480, encodeId=b276585480af, content=惊现审稿人Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿Dr. H 2020-02-14 00:00:00 发表: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, beContent=Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/0380108019204f323435b170194e7f28.jpg, createdBy=b43b5142498, createdName=1467c2d1m03暂无昵称, createdTime=Thu Feb 27 00:00:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120372, encodeId=99f921203e2d7, content=Proof ready 到invoice要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d74b8191744, createdName=ms2000000382061930, createdTime=Sun Mar 19 02:03:00 CST 2023, time=2023-03-19, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119810, encodeId=2b952119810ec, content=想问问一审大修之后还会修回给外审专家麽，还是编辑直接决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=008c8298477, createdName=ms1000001124557483, createdTime=Wed Mar 15 22:29:44 CST 2023, time=2023-03-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=914685, encodeId=5d0991468532, content=请问1月3号提交的手稿，现在还是submitted状态，是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72f5442032, createdName=ms9000000803041131, createdTime=Fri Jan 08 17:25:36 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后，在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省)]

2020-02-27 1467c2d1m03暂无昵称

惊现审稿人Dr. H 2020-02-14 发表::
Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿Dr. H 2020-02-14 00:00:00 发表:
Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿

Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿

49 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2098379, encodeId=dabe20983e9ce, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：9-24从oncology letter transfer过来，10-11小修，10-24返修，11-02润色后提交，11-03accept，一篇临床case，总体来说处理速度不慢，运气还不错，等待后续proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/02/c1a3d2d90ee1a88e8ee6415e4607e819.jpg, createdBy=e2622415808, createdName=Allen灬Walker, createdTime=Thu Nov 03 23:35:26 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145960, encodeId=7fd12145960c0, content=有人知道这个期刊最新情况嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/RHTJcPEoCibkIraBo1cDLcpFWGqcHzibDxMEgIvzKhO9uSnaZtFFLXcS9BhCsyX87KpoHViarOCD1Vn8dYL7RC3ng/0, createdBy=849a2163679, createdName=程南枫, createdTime=Sun Jul 02 15:13:46 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126420, encodeId=019f2126420f0, content=偏重的研究方向：基础 经验分享：Word版proof，引文怎么插入啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbc25508529, createdName=Ddffffg, createdTime=Mon Apr 17 06:41:27 CST 2023, time=2023-04-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127258, encodeId=988f212e2586d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：缺点是慢。审稿还是认真。尤其是编辑，审稿人没有什么意见，最后editor 提的问题对文章提升很用用。还有就是接收以后还不断提问。。。。没有说的那么烂吧，编辑还是在努力帮助提高文章质量, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=722f2896174, createdName=pinger3557219, createdTime=Thu Apr 20 14:47:41 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=585480, encodeId=b276585480af, content=惊现审稿人Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿Dr. H 2020-02-14 00:00:00 发表: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, beContent=Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/0380108019204f323435b170194e7f28.jpg, createdBy=b43b5142498, createdName=1467c2d1m03暂无昵称, createdTime=Thu Feb 27 00:00:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120372, encodeId=99f921203e2d7, content=Proof ready 到invoice要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d74b8191744, createdName=ms2000000382061930, createdTime=Sun Mar 19 02:03:00 CST 2023, time=2023-03-19, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119810, encodeId=2b952119810ec, content=想问问一审大修之后还会修回给外审专家麽，还是编辑直接决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=008c8298477, createdName=ms1000001124557483, createdTime=Wed Mar 15 22:29:44 CST 2023, time=2023-03-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=914685, encodeId=5d0991468532, content=请问1月3号提交的手稿，现在还是submitted状态，是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72f5442032, createdName=ms9000000803041131, createdTime=Fri Jan 08 17:25:36 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后，在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省)]

2023-03-19 ms2000000382061930 来自福建省

Proof ready 到invoice要多久啊

39 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2098379, encodeId=dabe20983e9ce, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：9-24从oncology letter transfer过来，10-11小修，10-24返修，11-02润色后提交，11-03accept，一篇临床case，总体来说处理速度不慢，运气还不错，等待后续proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/02/c1a3d2d90ee1a88e8ee6415e4607e819.jpg, createdBy=e2622415808, createdName=Allen灬Walker, createdTime=Thu Nov 03 23:35:26 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145960, encodeId=7fd12145960c0, content=有人知道这个期刊最新情况嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/RHTJcPEoCibkIraBo1cDLcpFWGqcHzibDxMEgIvzKhO9uSnaZtFFLXcS9BhCsyX87KpoHViarOCD1Vn8dYL7RC3ng/0, createdBy=849a2163679, createdName=程南枫, createdTime=Sun Jul 02 15:13:46 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126420, encodeId=019f2126420f0, content=偏重的研究方向：基础 经验分享：Word版proof，引文怎么插入啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbc25508529, createdName=Ddffffg, createdTime=Mon Apr 17 06:41:27 CST 2023, time=2023-04-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127258, encodeId=988f212e2586d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：缺点是慢。审稿还是认真。尤其是编辑，审稿人没有什么意见，最后editor 提的问题对文章提升很用用。还有就是接收以后还不断提问。。。。没有说的那么烂吧，编辑还是在努力帮助提高文章质量, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=722f2896174, createdName=pinger3557219, createdTime=Thu Apr 20 14:47:41 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=585480, encodeId=b276585480af, content=惊现审稿人Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿Dr. H 2020-02-14 00:00:00 发表: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, beContent=Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/0380108019204f323435b170194e7f28.jpg, createdBy=b43b5142498, createdName=1467c2d1m03暂无昵称, createdTime=Thu Feb 27 00:00:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120372, encodeId=99f921203e2d7, content=Proof ready 到invoice要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d74b8191744, createdName=ms2000000382061930, createdTime=Sun Mar 19 02:03:00 CST 2023, time=2023-03-19, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119810, encodeId=2b952119810ec, content=想问问一审大修之后还会修回给外审专家麽，还是编辑直接决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=008c8298477, createdName=ms1000001124557483, createdTime=Wed Mar 15 22:29:44 CST 2023, time=2023-03-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=914685, encodeId=5d0991468532, content=请问1月3号提交的手稿，现在还是submitted状态，是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72f5442032, createdName=ms9000000803041131, createdTime=Fri Jan 08 17:25:36 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后，在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省)]

2023-03-15 ms1000001124557483 来自湖南省

想问问一审大修之后还会修回给外审专家麽，还是编辑直接决定

24 0

[GetPortalCommentsPageByObjectIdResponse(id=2098379, encodeId=dabe20983e9ce, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：9-24从oncology letter transfer过来，10-11小修，10-24返修，11-02润色后提交，11-03accept，一篇临床case，总体来说处理速度不慢，运气还不错，等待后续proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/02/c1a3d2d90ee1a88e8ee6415e4607e819.jpg, createdBy=e2622415808, createdName=Allen灬Walker, createdTime=Thu Nov 03 23:35:26 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145960, encodeId=7fd12145960c0, content=有人知道这个期刊最新情况嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/RHTJcPEoCibkIraBo1cDLcpFWGqcHzibDxMEgIvzKhO9uSnaZtFFLXcS9BhCsyX87KpoHViarOCD1Vn8dYL7RC3ng/0, createdBy=849a2163679, createdName=程南枫, createdTime=Sun Jul 02 15:13:46 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126420, encodeId=019f2126420f0, content=偏重的研究方向：基础 经验分享：Word版proof，引文怎么插入啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbc25508529, createdName=Ddffffg, createdTime=Mon Apr 17 06:41:27 CST 2023, time=2023-04-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127258, encodeId=988f212e2586d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：缺点是慢。审稿还是认真。尤其是编辑，审稿人没有什么意见，最后editor 提的问题对文章提升很用用。还有就是接收以后还不断提问。。。。没有说的那么烂吧，编辑还是在努力帮助提高文章质量, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=722f2896174, createdName=pinger3557219, createdTime=Thu Apr 20 14:47:41 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=585480, encodeId=b276585480af, content=惊现审稿人Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿Dr. H 2020-02-14 00:00:00 发表: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, beContent=Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/0380108019204f323435b170194e7f28.jpg, createdBy=b43b5142498, createdName=1467c2d1m03暂无昵称, createdTime=Thu Feb 27 00:00:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120372, encodeId=99f921203e2d7, content=Proof ready 到invoice要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d74b8191744, createdName=ms2000000382061930, createdTime=Sun Mar 19 02:03:00 CST 2023, time=2023-03-19, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119810, encodeId=2b952119810ec, content=想问问一审大修之后还会修回给外审专家麽，还是编辑直接决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=008c8298477, createdName=ms1000001124557483, createdTime=Wed Mar 15 22:29:44 CST 2023, time=2023-03-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=914685, encodeId=5d0991468532, content=请问1月3号提交的手稿，现在还是submitted状态，是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72f5442032, createdName=ms9000000803041131, createdTime=Fri Jan 08 17:25:36 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后，在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省)]

2021-01-08 ms9000000803041131

请问1月3号提交的手稿，现在还是submitted状态，是正常的吗

102 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2098379, encodeId=dabe20983e9ce, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：9-24从oncology letter transfer过来，10-11小修，10-24返修，11-02润色后提交，11-03accept，一篇临床case，总体来说处理速度不慢，运气还不错，等待后续proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/02/c1a3d2d90ee1a88e8ee6415e4607e819.jpg, createdBy=e2622415808, createdName=Allen灬Walker, createdTime=Thu Nov 03 23:35:26 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145960, encodeId=7fd12145960c0, content=有人知道这个期刊最新情况嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/RHTJcPEoCibkIraBo1cDLcpFWGqcHzibDxMEgIvzKhO9uSnaZtFFLXcS9BhCsyX87KpoHViarOCD1Vn8dYL7RC3ng/0, createdBy=849a2163679, createdName=程南枫, createdTime=Sun Jul 02 15:13:46 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2126420, encodeId=019f2126420f0, content=偏重的研究方向：基础 经验分享：Word版proof，引文怎么插入啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbc25508529, createdName=Ddffffg, createdTime=Mon Apr 17 06:41:27 CST 2023, time=2023-04-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1189522, encodeId=081e1189522a8, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：基础研究;糖尿病 经验分享：一个单纯的细胞实验，中间做了个通路加了抑制剂。外审大约4周，审稿人其实很认真。提了很多有帮助的意见，七天后修回。编辑又提了十几个问题。按照意见修改后接受。版面费不是很贵，今年从中科院预警中出来了。总的来说，杂志水平很一般，但是着急毕业的可以投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6e35408773, createdName=ms2000000130062631, createdTime=Tue Feb 01 06:47:19 CST 2022, time=2022-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127258, encodeId=988f212e2586d, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：缺点是慢。审稿还是认真。尤其是编辑，审稿人没有什么意见，最后editor 提的问题对文章提升很用用。还有就是接收以后还不断提问。。。。没有说的那么烂吧，编辑还是在努力帮助提高文章质量, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=722f2896174, createdName=pinger3557219, createdTime=Thu Apr 20 14:47:41 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=585480, encodeId=b276585480af, content=惊现审稿人Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿Dr. H 2020-02-14 00:00:00 发表: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, beContent=Dr. H 2020-02-14 发表:: Spandidos几乎所有journal我都审过，都很水，而且从来不剧稿, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/03/0380108019204f323435b170194e7f28.jpg, createdBy=b43b5142498, createdName=1467c2d1m03暂无昵称, createdTime=Thu Feb 27 00:00:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2120372, encodeId=99f921203e2d7, content=Proof ready 到invoice要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d74b8191744, createdName=ms2000000382061930, createdTime=Sun Mar 19 02:03:00 CST 2023, time=2023-03-19, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2119810, encodeId=2b952119810ec, content=想问问一审大修之后还会修回给外审专家麽，还是编辑直接决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=008c8298477, createdName=ms1000001124557483, createdTime=Wed Mar 15 22:29:44 CST 2023, time=2023-03-15, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=914685, encodeId=5d0991468532, content=请问1月3号提交的手稿，现在还是submitted状态，是正常的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72f5442032, createdName=ms9000000803041131, createdTime=Fri Jan 08 17:25:36 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2110484, encodeId=f1632110484f8, content=大家做好接收后，在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/05/28/131c98d903b8e5db2b7486caf38332d6.jpg, createdBy=c9991729217, createdName=氢弹, createdTime=Tue Jan 17 00:05:22 CST 2023, time=2023-01-17, status=1, ipAttribution=四川省)]

2023-01-17 氢弹来自四川省

大家做好接收后，在PROOF过程中找各种问题后拒绝出版的情况。反正以后是再也不会投该杂志了。

33 5

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务